drugset / Trial / NCT05739903
Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fasting State
RandomizedCrossoverOpen-labelTreatment
Summary
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229\_01 (5/1000 mg x1 tablets) at fasting state.
Timeline
- Start
- 2023-03-25
- Primary completion
- 2023-04-21
- Completion
- 2023-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-1229_01 | Unknown | — | — |
Indications
No indication recorded.